Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 5/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231678 | 0.95 | EPHX2 (0.59) | EPHX2MMP3MMP8MMP9MMP1 | |
| SCHEMBL18381491 | 0.94 | EPHX2 (0.61) | EPHX2MMP3MMP8MMP9MMP1 | |
| SCHEMBL24207892 | 0.87 | MMP3 (0.47) | EPHX2MMP3MMP8MMP9MMP1 | |
| SCHEMBL22297314 | 0.86 | MMP3 (0.52) | EPHX2MMP3MMP8MMP9MMP1 | |
| SCHEMBL20322529 | 0.86 | TAAR1 (0.51) | SMN1; SMN2TAAR1LMNA | |
| SCHEMBL20818936 | 0.84 | EPHX2 (0.51) | EPHX2SMN1; SMN2HTTTAAR1NAAA | |
| SCHEMBL13902888 | 0.84 | EPHX2 (0.53) | EPHX2LTA4HSMN1; SMN2HTTTAAR1 | |
| SCHEMBL8247495 | 0.83 | SMN1; SMN2 (0.52) | EPHX2MMP3MMP8MMP9MMP1 | |
| SCHEMBL17117263 | 0.83 | GAA (0.70) | EPHX2HTTGAALMNAMEN1 | |
| SCHEMBL22297177 | 0.82 | MMP3 (0.48) | MMP3MMP8MMP9MMP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970334-B1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | EPHX2 3700/4885MMP3 3879/4885MMP8 4286/4885 |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK4, IRAK1, IRAK2 | EPHX2 4076/4885MMP3 4711/4885MMP8 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.